Note: This document contains side effect information about meropenem. Some of the dosage forms listed on this page may not apply to the brand name Merrem.
Applies to meropenem: intravenous powder for solution
Along with its needed effects, meropenem (the active ingredient contained in Merrem) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking meropenem:
Incidence not known
Some side effects of meropenem may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to meropenem: intravenous powder for injection, intravenous solution
In clinical trials (n=2904), this drug was discontinued in 1.2% of patients due to side effects; 5 deaths were possibly drug-related. In a review of 4872 patients, diarrhea, rash, nausea/vomiting, injection site inflammation, thrombocytosis and increased hepatic enzymes were reported most often.
Common (1% to 10%): Nausea, diarrhea, vomiting, constipation, gastrointestinal disorder, abdominal pain
Uncommon (0.1% to 1%): Oral moniliasis/candidiasis, flatulence, ileus, dyspepsia, intestinal obstruction
Frequency not reported: Clostridium difficile associated diarrhea, antibiotic-associated colitis, pseudomembranous colitis
Common (1% to 10%): Headache
Uncommon (0.1% to 1%): Dizziness, seizure, paresthesia, somnolence, syncope, asthenia
Frequency not reported: Hearing loss, other adverse central nervous system (CNS) experiences
Seizures and other adverse CNS experiences have been reported. They have occurred most commonly in patients with CNS disorders (e.g., history of seizures, brain lesions) or with bacterial meningitis and/or renal dysfunction.
Seizures occurred more often in patients with moderately severe renal dysfunction.
Common (1% to 10%): Anemia, hypochromic anemia, bleeding events (including gastrointestinal hemorrhage, melena, epistaxis, hemoperitoneum), thrombocythemia
Uncommon (0.1% to 1%): Increased platelets, increased eosinophils, decreased platelets, decreased hemoglobin, decreased hematocrit, decreased white blood cells, decreased prothrombin time, decreased partial thromboplastin time, leukocytosis, eosinophilia, thrombocytopenia, leukopenia, neutropenia
Postmarketing reports: Agranulocytosis, positive Coombs test (direct or indirect), hemolytic anemia
Shock occurred more often in patients with moderately severe renal dysfunction.
Common (1% to 10%): Pain, inflammation, sepsis/septicemia, shock, accidental injury
Uncommon (0.1% to 1%): Chest pain, fever, back pain, chills, pelvic pain, peripheral edema, abdominal enlargement
Common (1% to 10%): Inflammation at the injection site, phlebitis/thrombophlebitis, pain at the injection site
Uncommon (0.1% to 1%): Injection site reactions, edema at the injection site
Common (1% to 10%): Rash (including diaper/nappy area moniliasis), pruritus
Uncommon (0.1% to 1%): Urticaria, sweating, skin ulcer
Postmarketing reports: Toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema, erythema multiforme, severe skin reactions
Common (1% to 10%): Apnea, pharyngitis, pneumonia
Uncommon (0.1% to 1%): Respiratory disorder, dyspnea, pleural effusion, asthma, increased cough, hypoxia, lung edema
Frequency not reported: Respiratory failure
Heart failure occurred more often in patients with moderately severe renal dysfunction.
Common (1% to 10%): Peripheral vascular disorder
Uncommon (0.1% to 1%): Heart failure, heart arrest, tachycardia, hypertension, myocardial infarction, pulmonary embolus, bradycardia, hypotension
Common (1% to 10%): Increased transaminases
Uncommon (0.1% to 1%): Increased AST, increased ALT, increased bilirubin, hepatic failure, cholestatic jaundice/jaundice
Common (1% to 10%): Hypoglycemia, increased alkaline phosphatase, increased lactate dehydrogenase
Uncommon (0.1% to 1%): Anorexia, hypervolemia, hypokalemia
Kidney failure occurred more often in patients with moderately severe renal dysfunction.
Uncommon (0.1% to 1%): Kidney failure, increased creatinine, increased BUN
Uncommon (0.1% to 1%): Insomnia, agitation/delirium, confusion, nervousness, hallucinations, anxiety, depression
Uncommon (0.1% to 1%): Dysuria, vaginal moniliasis/candidiasis, urinary incontinence, red blood cells in urine
Frequency not reported: Serum sickness-like reactions, cross-sensitivity in penicillin-allergic and cephalosporin-allergic patients, anaphylaxis
Frequency not reported: Myalgia, arthralgia
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Merrem